Suppr超能文献

肝细胞癌的当代流行病学:了解风险因素和监测策略。

Contemporary epidemiology of hepatocellular carcinoma: understanding risk factors and surveillance strategies.

作者信息

Jaber Fouad, Cholankeril George, El-Serag Hashem B

机构信息

Department of Internal Medicine, Section of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, TX 77030, United States.

出版信息

J Can Assoc Gastroenterol. 2024 Aug 9;7(5):331-345. doi: 10.1093/jcag/gwae025. eCollection 2024 Oct.

Abstract

The contemporary epidemiology of hepatocellular carcinoma (HCC) shows a shift in the main etiological risk factors from less common but highly virulent (eg, hepatitis C and B) to more common but weak risk factors (eg, alcohol and metabolic syndrome). Therefore, we are in a seemingly paradoxical state of declining overall incidence rates of HCC-related to improved prevention and treatment of viral hepatitis but burgeoning number of people at an elevated risk of HCC. Several geographic regions have reported an increase in HCC attributable to alcoholic liver disease and metabolic dysfunction associated with steatotic liver disease (MASLD). The importance of risk stratification is increasing to allow for targeted prevention and early detection of HCC. Most risk factors predispose HCC through the formation of cirrhosis, which has served as the main risk stratifying factor. However, this scheme is showing cracks at both ends of the spectrum. On one hand, the risk of developing HCC varies widely among patients with contemporary advanced fibrosis or cirrhosis, and on the other hand up to one-third of MASLD-related HCC occurs among patients with no clear evidence of cirrhosis. The use of multidimensional (eg, clinical, epidemiological, and biochemical) predictive algorithms may improve risk stratification efforts. The shift in HCC risk factors also further heightened the importance and limitations of current surveillance practices (eg, reduced performance of ultrasound in MASLD). Therefore, exploring advanced imaging methods, new biomarkers but also existing combinations of biomarkers augmented by clinical factors for HCC early detection is crucial.

摘要

肝细胞癌(HCC)的当代流行病学显示,主要病因风险因素发生了转变,从不太常见但毒性很强的因素(如丙型和乙型肝炎)转变为更常见但风险较弱的因素(如酒精和代谢综合征)。因此,我们处于一种看似矛盾的状态:与病毒性肝炎预防和治疗改善相关的HCC总体发病率下降,但HCC风险升高的人数却在迅速增加。几个地理区域报告称,酒精性肝病和与脂肪性肝病相关的代谢功能障碍(MASLD)导致的HCC有所增加。风险分层的重要性日益增加,以便进行有针对性的HCC预防和早期检测。大多数风险因素通过肝硬化的形成使患者易患HCC,肝硬化一直是主要的风险分层因素。然而,这一方案在范围的两端都出现了问题。一方面,当代晚期纤维化或肝硬化患者发生HCC的风险差异很大,另一方面,高达三分之一的MASLD相关HCC发生在没有明确肝硬化证据的患者中。使用多维(如临床、流行病学和生化)预测算法可能会改善风险分层工作。HCC风险因素的转变也进一步凸显了当前监测实践的重要性和局限性(如超声在MASLD中的性能下降)。因此,探索先进的成像方法、新的生物标志物以及结合临床因素增强现有生物标志物组合以实现HCC早期检测至关重要。

相似文献

1
Contemporary epidemiology of hepatocellular carcinoma: understanding risk factors and surveillance strategies.
J Can Assoc Gastroenterol. 2024 Aug 9;7(5):331-345. doi: 10.1093/jcag/gwae025. eCollection 2024 Oct.
2
NIH Consensus Statement on Management of Hepatitis C: 2002.
NIH Consens State Sci Statements. 2002;19(3):1-46.
3
Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis.
Health Technol Assess. 2007 Sep;11(34):1-206. doi: 10.3310/hta11340.
4
Ultrasonography for diagnosis of alcoholic cirrhosis in people with alcoholic liver disease.
Cochrane Database Syst Rev. 2016 Mar 2;3(3):CD011602. doi: 10.1002/14651858.CD011602.pub2.
6
Contrast-enhanced ultrasound for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.
Cochrane Database Syst Rev. 2022 Sep 2;9(9):CD013483. doi: 10.1002/14651858.CD013483.pub2.
8
Systemic treatments for metastatic cutaneous melanoma.
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
10
Interventions to improve safe and effective medicines use by consumers: an overview of systematic reviews.
Cochrane Database Syst Rev. 2014 Apr 29;2014(4):CD007768. doi: 10.1002/14651858.CD007768.pub3.

本文引用的文献

1
Disparities in stage at diagnosis for liver cancer in China.
J Natl Cancer Cent. 2023 Jan 3;3(1):7-13. doi: 10.1016/j.jncc.2022.12.002. eCollection 2023 Mar.
2
HES V2.0 outperforms GALAD for detection of HCC: A phase 3 biomarker study in the United States.
Hepatology. 2025 Feb 1;81(2):465-475. doi: 10.1097/HEP.0000000000000953. Epub 2024 Jun 19.
3
Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide.
J Liver Cancer. 2024 Mar;24(1):62-70. doi: 10.17998/jlc.2024.03.13. Epub 2024 Mar 25.
4
Hepatocellular Carcinoma Incidence and Mortality in the USA by Sex, Age, and Race: A Nationwide Analysis of Two Decades.
J Clin Transl Hepatol. 2024 Feb 28;12(2):172-181. doi: 10.14218/JCTH.2023.00356. Epub 2024 Jan 2.
5
HCC is associated with diabetes and longitudinal blood glucose control in a national cohort with cirrhosis.
Hepatol Commun. 2023 Dec 7;7(12). doi: 10.1097/HC9.0000000000000344. eCollection 2023 Dec 1.
6
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.
Hepatology. 2023 Dec 1;78(6):1922-1965. doi: 10.1097/HEP.0000000000000466. Epub 2023 May 22.
7
Global Epidemiology and Genetics of Hepatocellular Carcinoma.
Gastroenterology. 2023 Apr;164(5):766-782. doi: 10.1053/j.gastro.2023.01.033. Epub 2023 Feb 2.
8
Hepatocellular Carcinoma in Primary Biliary Cholangitis.
Clin Liver Dis. 2022 Nov;26(4):691-704. doi: 10.1016/j.cld.2022.06.011.
10
Recent Decline in the Incidence of Hepatocellular Carcinoma in the United States.
Clin Gastroenterol Hepatol. 2023 Aug;21(9):2418-2420.e3. doi: 10.1016/j.cgh.2022.07.034. Epub 2022 Aug 6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验